C-reactive Protein Testing Market Size, Share, Growth, Trends, Forecast 2021 to 2030

The global c-reactive protein testing market size is expected to be worth around US$ 10.6 billion by 2030, according to a new report by Vision Research Reports.

The global c-reactive protein testing market size was valued at US$ 8.5 billion in 2020 and is anticipated to grow at a CAGR of 0.6% during forecast period 2021 to 2030.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38686

Growth Factors

The market growth can be attributed to substantial research activities to explore the applications of C-reactive protein (CRP) testing coupled with the presence of private as well as public agencies which grant funds to expedite the research proceedings in this arena.

A rise in the number of strategic deals and developments coupled with the increase in investments for R&D of C-reactive protein testing is expected to drive the market significantly. The ongoing COVID-19 pandemic has affected the CRP testing market to a great extent. As CRP is considered to be the determining biomarker for the severity of infection/inflammation, the market is witnessing increased demand for CRP testing services and products. Major operating companies such as Abbott offer supportive tools for CRP testing for SARS-CoV-2 infection.

Report Coverage

By Assay Type Analysis

The immunoturbidimetric assays dominated the market and accounted for the largest revenue share of 48.5% in 2020. The segment is anticipated to further grow during the forecast period.

Technological advancements in immunoturbidimetric assays are expected to fuel market growth in the coming years. Researchers across the world are actively involved in the development of advanced and innovative assays to support rapid and accurate CRP testing.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/38686

By Detection Range Analysis

The hs-CRP segment dominated the CRP testing market and accounted for the largest revenue share of 42.8% in 2020. The segment is anticipated to witness a CAGR of 0.3% from 2021 - 2028.

American Heart Association (AHA) and Centers for Disease Control and Prevention (CDC), hs-CRP acts as an independent marker that facilitates in the estimation of cardiovascular disorders such as myocardial infarction.

By Disease Type Analysis

The Cardiovascular diseases (CVD) segment lead the market and accounted for the largest revenue share of 22.8% in 2020. An increase in the prevalence of CVDs is the major factor contributing to the growth of the market. Adoption of a sedentary lifestyle, obesity, hypertension, and diabetes are few risk factors associated with CVDs.

The cancer segment held the second-largest revenue share in 2020. It is a crucial public health burden across the globe. According to the WHO, there are more than 1.9 million deaths and 3.7 million new cancer cases every year in the European region, hence, there is a need for large-scale adoption of POC CRP testing solutions to aid in the management of cancer in developed and developing countries across the globe.

By End-use Analysis

The hospitals segment dominated the market and lead for the largest revenue share of 31.2% in 2020. The growth of the hospitals segment can be attributed to the rising penetration of CRP testing in hospitals, especially in developing regions across the world.

The clinics segment held a substantial market share throughout the analysis period. CRP testing technology has expanded in the past few years with noteworthy developments in areas of point-of-care and hs-CRP.

By Regional Analysis

North America dominated the C-reactive protein testing market and accounted for the highest revenue share of 40.5% in 2020. Increasing adoption of innovative, advanced technology and high focus on clinical research in North America are among the factors driving the market.

According to the American Cancer Society, prostate cancer is the second most diagnosed cancer in the U.S. and the third leading cause of death in men. Estimates from the same source also indicated that one in 41 men in the U.S. will die as a result of prostate cancer.

Related Reports

• Protein Crystallization Market Report 2022-2030 - https://www.visionresearchreports.com/protein-crystallization-market/39912
• Proteinase K Market Report 2022-2030 - https://www.visionresearchreports.com/proteinase-k-market/39817
• Protein Sequencing Market Report 2022-2030 - https://www.visionresearchreports.com/protein-sequencing-market/39776

Key Players

• Thermo Fisher Scientific, inc.
• F. Hoffmann-La Roche Ltd.
• Danaher
• Quest Diagnostics
• Siemens Healthineers AG
• Abbott
• Merck KGaAA
• Zoetis
• Ortho Clinical Diagnostics
• Getein Biotech, Inc.
• HORIBA, Ltd
• Randox Laboratories Ltd.
• BODITECH MED, INC.
• Aidian

Market Segmentation

• Assay Type
  • Immunoturbidimetric Assay
  • ELISA
    • Clinical
    • Non-clinical
  • Chemiluminescence Immunoassay
  • Others
• Detection Range
  • hs-CRP
  • Conventional CRP
  • cCRP
• Disease Area
  • Cardiovascular Diseases
  • Cancer
  • Rheumatoid Arthritis
  • Inflammatory Bowel Disease
  • Endometriosis
  • Lupus
  • Others
• End-use
  • Clinics
    • By Entity
      • Physician Offices
      • Small Clinics
      • Others
    • By Settings
      • Urban Setting
      • Rural Setting
  • Hospitals
    • Urban Setting
    • Rural Setting
  • Laboratories
    • Urban Setting
    • Rural Setting
  • Assisted Living Healthcare Facilities
    • Urban Setting
    • Rural Setting
  • Home
  • Others
• Regional
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

Click Here to View Full Report Table of Contents

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/38686

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://qyresearchmedical.com/